AMPH Stock Analysis: Amphastar P | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.253m USD | 12M Return: 11.4% | US03209R1032 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.5M
EPS Trend: -80.8%
Qual. Beats: 2
Rev. Trend: 74.1%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, operating primarily in the United States, China, and France. Founded in 1996 and headquartered in Rancho Cucamonga, California, the company has been public since its 2014 IPO.
The company markets a diverse portfolio spanning emergency care, hospital products, and chronic disease treatments, including BAQSIMI (nasal glucagon for severe hypoglycemia), Primatene MIST (epinephrine inhaler for asthma), Enoxaparin (low molecular weight heparin for thrombosis), and Naloxone products for opioid overdose. Its hospital and diagnostic offerings include Cortrosyn, Amphadase, Lidocaine formulations, Phytonadione injection, and prefilled emergency syringes, while respiratory and chronic-disease products include Albuterol, Ipratropium Bromide HFA, Iron sucrose, and Teriparatide. The company also produces active pharmaceutical ingredients such as Recombinant Human Insulin and porcine insulin API.
- BAQSIMI glucagon nasal spray revenue grows on diabetes prevalence
- Enoxaparin generic injectable margins face increased competition
- China and France international sales currency and regulatory risks
- Primatene MIST and inhalation aerosol demand seasonal variability
- FDA approval pipeline for new injectable and intranasal products
- Capital allocation through buybacks and R&D spending pressures margins
| Net Income: 99.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.32 > 1.0 |
| NWC/Revenue: 56.48% < 20% (prev 60.04%; Δ -3.55% < -1%) |
| CFO/TA 0.10 > 3% & CFO 175.3m > Net Income 99.0m |
| Net Debt (539.7m) to EBITDA (220.7m): 2.45 < 3 |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.4m) vs 12m ago -9.02% < -2% |
| Gross Margin: 46.81% > 18% (prev 49.36%; Δ -2.55% > 0.5%) |
| Asset Turnover: 44.16% > 50% (prev 43.41%; Δ 0.75% > 0%) |
| Interest Coverage Ratio: 5.87 > 6 (EBIT TTM 156.2m / Interest Expense TTM 26.6m) |
| A: 0.25 (Total Current Assets 602.7m - Total Current Liabilities 181.4m) / Total Assets 1.71b |
| B: 0.43 (Retained Earnings 741.4m / Total Assets 1.71b) |
| C: 0.09 (EBIT TTM 156.2m / Avg Total Assets 1.69b) |
| D: 0.91 (Book Value of Equity 814.6m / Total Liabilities 897.2m) |
| Altman-Z'' = 4.60 = AA |
| DSRI: 1.20 (Receivables 182.2m/146.8m, Revenue 745.8m/723.3m) |
| GMI: 1.05 (GM 49.36% / 46.81%) |
| AQI: 1.04 (AQ_t 0.42 / AQ_t-1 0.40) |
| SGI: 1.03 (Revenue 745.8m / 723.3m) |
| TATA: -0.04 (NI 99.0m - CFO 175.3m) / TA 1.71b) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of November 21, 2026, the stock is trading at USD 28.25 with a total of 498,484 shares traded. Over the past week, the price has changed by -3.81%, over one month by +8.91%, over three months by +30.30% and over the past year by +11.40%.
Current recommended Stop Loss: 26.70 (which is 5.5% or 1.4 ATR below the current price).
Amphastar P has received a consensus analysts rating of 2.86. Therefore, it is recommended to hold AMPH.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 24.5 | -13.3% |
P/E Trailing = 13.4725
P/S = 1.6795
P/B = 1.4974
P/EG = 2.77
Revenue TTM = 745.8m USD
EBIT TTM = 156.2m USD
EBITDA TTM = 220.7m USD
Long Term Debt = 610.5m USD (from longTermDebt, last quarter)
Short Term Debt = 11.2m USD (from shortTermDebt, last quarter)
Debt = 770.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 78.7m
Net Debt = 539.7m USD (calculated: Debt 770.4m - CCE 230.6m)
Enterprise Value = 1.79b USD (1.25b + Debt 770.4m - CCE 230.6m)
Interest Coverage Ratio = 5.87 (Ebit TTM 156.2m / Interest Expense TTM 26.6m)
EV/FCF = 12.89x (Enterprise Value 1.79b / FCF TTM 139.0m)
FCF Yield = 7.76% (FCF TTM 139.0m / Enterprise Value 1.79b)
FCF Margin = 18.64% (FCF TTM 139.0m / Revenue TTM 745.8m)
Net Margin = 13.27% (Net Income TTM 99.0m / Revenue TTM 745.8m)
Gross Margin = 46.81% ((Revenue TTM 745.8m - Cost of Revenue TTM 396.7m) / Revenue TTM)
Gross Margin QoQ = 47.99% (prev 50.83%)
Tobins Q-Ratio = 1.05 (Enterprise Value 1.79b / Total Assets 1.71b)
Interest Expense / Debt = 3.45% (Interest Expense 26.6m / Debt 770.4m)
Taxrate = 23.63% (30.6m / 129.6m)
NOPAT = 119.3m (EBIT 156.2m * (1 - 23.63%))
Current Ratio = 3.32 (Total Current Assets 602.7m / Total Current Liabilities 181.4m)
Debt / Equity = 0.95 (Debt 770.4m / totalStockholderEquity, last quarter 814.6m)
Debt / EBITDA = 2.45 (Net Debt 539.7m / EBITDA 220.7m)
Debt / FCF = 3.88 (Net Debt 539.7m / FCF TTM 139.0m)
Total Stockholder Equity = 786.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.86% (Net Income 99.0m / Total Assets 1.71b)
RoE = 12.59% (Net Income TTM 99.0m / Total Stockholder Equity 786.2m)
RoCE = 11.18% (EBIT 156.2m / Capital Employed (Equity 786.2m + L.T.Debt 610.5m))
RoIC = 7.93% (NOPAT 119.3m / Invested Capital 1.50b)
WACC = 5.89% (E(1.25b)/V(2.02b) * Re(7.89%) + D(770.4m)/V(2.02b) * Rd(3.45%) * (1-Tc(0.24)))
Discount Rate = 7.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.92 | Cagr: -7.78%
[DCF] Terminal Value 77.97% ; FCFF base≈128.7m ; Y1≈147.5m ; Y5≈217.1m
[DCF] Fair Price = 63.96 (EV 3.27b - Net Debt 539.7m = Equity 2.73b / Shares 42.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -80.78 | EPS CAGR: -11.49% | SUE: 1.07 | # QB: 2
Revenue Correlation: 74.09 | Revenue CAGR: 3.31% | SUE: 2.26 | # QB: 1
EPS current Quarter (2027-03-31): EPS=0.72 | Chg30d=+1.05% | Revisions=+29% | Analysts=4
EPS current Year (2026-12-31): EPS=3.16 | Chg30d=+6.20% | Revisions=-25% | GrowthEPS=-2.9% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=2.64 | Chg30d=+50.00% | Revisions=-25% | GrowthEPS=+21.7% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +0% (up=3, down=3)